



香港城市大學
City University of Hong Kong

專業 創新 胸懷全球
Professional · Creative
For The World

CityU Scholars

Post-recovery enhancement of anti-variant neutralisation after severe COVID-19

Lu, Yingying; Zhu, Yufang; Cui, Miao; Cheng, Zhengjiang; Hong, Peng

Published in:

The Lancet Microbe

Published: 01/05/2022

Document Version:

Final Published version, also known as Publisher's PDF, Publisher's Final version or Version of Record

License:

CC BY-NC-ND

Publication record in CityU Scholars:

[Go to record](#)

Published version (DOI):

[10.1016/S2666-5247\(22\)00032-5](https://doi.org/10.1016/S2666-5247(22)00032-5)

Publication details:

Lu, Y., Zhu, Y., Cui, M., Cheng, Z., & Hong, P. (2022). Post-recovery enhancement of anti-variant neutralisation after severe COVID-19. *The Lancet Microbe*, 3(5), e330-e331. [https://doi.org/10.1016/S2666-5247\(22\)00032-5](https://doi.org/10.1016/S2666-5247(22)00032-5)

Citing this paper

Please note that where the full-text provided on CityU Scholars is the Post-print version (also known as Accepted Author Manuscript, Peer-reviewed or Author Final version), it may differ from the Final Published version. When citing, ensure that you check and use the publisher's definitive version for pagination and other details.

General rights

Copyright for the publications made accessible via the CityU Scholars portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Users may not further distribute the material or use it for any profit-making activity or commercial gain.

Publisher permission

Permission for previously published items are in accordance with publisher's copyright policies sourced from the SHERPA RoMEO database. Links to full text versions (either Published or Post-print) are only available if corresponding publishers allow open access.

Take down policy

Contact lbscholars@cityu.edu.hk if you believe that this document breaches copyright and provide us with details. We will remove access to the work immediately and investigate your claim.

Post-recovery enhancement of anti-variant neutralisation after severe COVID-19

Improving the durability and breadth of vaccine-induced neutralising antibodies against immune-evasive SARS-CoV-2 variants is a pressing need when cases of the heavily mutated omicron variant are surging at an unprecedented rate (appendix pp 8–9). In view of the broadly reactive neutralising antibodies identified in vaccine-boosted individuals with previous SARS-CoV-2 infection,¹ researchers have found that prolonged or repeated SARS-CoV-2 antigen exposure, such as those seen in repeated or breakthrough infections, could improve antibody affinity to emerging variants via enhancing affinity maturation.^{2,3} Given that convalescent sera from standard COVID-19 cohorts has performed poorly in neutralising omicron,^{4,5} we wonder whether more severe disease courses could induce durable and effective neutralising antibodies against omicron and other immune-evasive variants by affinity maturation.

We studied two prospective cohorts of patients recovered from severe COVID-19 (n=18) and vaccinated health-care workers without a history of COVID-19 (n=24) in Xiangyang, China (appendix p 2). Recovered patients had contracted SARS-CoV-2 during the first outbreak and were not vaccinated before the study. The health-care workers had been vaccinated with CoronaVac (Sinovac Biotech, Beijing, China; n=12) or BBIBP-CorV (Sinopharm, Beijing, China; n=12), both of which are two-dose inactivated vaccines. In serum samples we analysed total antibody concentrations against SARS-CoV-2 receptor-binding domain (RBD) and pseudovirus neutralisation titres (pNT₅₀; calculated as the half-maximal effective concentration) of circulating variants and the ancestral

Wuhan-Hu-1 strain. Convalescent sera of recovered patients was collected at 1 month and 12 months after recovery, and compared with the sera of the health-care worker group who were followed-up at 1 month and 6 months after full vaccination (appendix p 7). All samples in the present study were randomly chosen from seropositive cohorts. Further details on the study protocol are provided in the appendix (pp 2–6).

As expected, convalescent sera showed a 2.7-times decrease in geometric mean signal or positive cutoff ratios of anti-RBD antibodies and a 9.0-times decrease in geometric mean pNT₅₀ (GMT) of Wuhan-Hu-1 from 1 month to 12 months after recovery, sharing a similar (normal) decay pattern with that of vaccinated sera from 1 month to 6 months after vaccination (appendix p 10). Between 1 month and 12 months, convalescent sera showed similar GMTs of immune-evasive variants omicron (p=0.35), mu (p=1.0), and gamma (p=0.65); whereas, neutralisation of the less evasive delta (p=0.0016) and lambda (p<0.0001) variants was less durable and decreased in parallel with Wuhan-Hu-1 neutralisation (p<0.0001; appendix pp 11–12). Thus, severe infection might induce an enhancement of antibody affinity to immune-evasive variants between 1 month and 12 months after recovery. By contrast, GMTs of both CoronaVac and BBIBP-CorV sera showed consistently decreasing trends across tested variants over time, although the decrease in some longitudinal pairs did not reach statistical significance due to sample size or the limit of detection (appendix p 11). When comparing late versus early GMT ratios (month 12 vs month 1 ratio, or month 6 vs month 1 ratio) across variants, we observed that 16 (89%) of 18 samples of 12-month convalescent sera had omicron ratios consistent with (within a 2-fold range) or higher (>2 fold) than each corresponding 1-month ratio, which was distinct to BBIBP-CorV

sera (one [17%] of six, p=0.0027 vs convalescent) and CoronaVac sera (two [20%] of ten, p=0.0005 vs convalescent) after excluding 1-month samples with a GMT less than 1.0 (appendix pp 13–14). This enhanced neutralisation at 12-month convalescence was also observed for gamma and mu, while vaccinated sera showed no such enhancement at 6 months (appendix pp 13–14).

These data provide evidence of long-term enhancement of antibody affinity to immune-evasive SARS-CoV-2 variants, which might be unique to survivors of severe COVID-19. The underlying mechanism could be utilised to improve vaccine efficacy against emerging variants.

We declare no competing interests.

YL and YZ contributed equally. YL and PH conceived and designed the study, conducted neutralisation assays and statistical analyses, and wrote this piece. YZ and ZC recruited participants, collected specimens, conducted clinical laboratory tests, and interpreted findings. MC assisted with statistical analyses and conducted data quality checks. YL, YZ, and PH accessed and verified the data. All authors had full access to all the data, read and approved the final version, and accept responsibility to submit for publication. This study was supported by the National Key Research & Development Program of China (grant number 2017YFC1105000), the National Natural Science Foundation of China (grant number 31501116), and the US Department of Veterans Affairs (grant number 5J01BX001353). The funding sources had no role in the study or preparation of this work. No authors were precluded from accessing data in the study. We thank the nurses and technicians at the Department of Laboratory Medicine of Xiangyang Central Hospital for their assistance in participant enrolment, blood collection, and sample preparation.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Yingying Lu, Yufang Zhu, Miao Cui, Zhengjiang Cheng, *Peng Hong peng.hong@downstate.edu

Center for Nephrology at the Seventh Hospital, Sun Yat-sen University, Shenzhen, China (YL, PH); Department of Biomedical Science, City University of Hong Kong, Kowloon Tong, Hong Kong Special Administrative Region, China (YL); Laboratory of Clinical Immunology, Department of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China (YZ, ZC); Department of Pathology, Mount Sinai St Luke's Roosevelt Hospital Center, New York, NY, USA (MC); Division of Research and Development, US Department of Veterans Affairs New York Harbor Healthcare



Published Online
February 7, 2022
[https://doi.org/10.1016/S2666-5247\(22\)00032-5](https://doi.org/10.1016/S2666-5247(22)00032-5)

See Online appendix

System, Brooklyn, NY 11209, USA (PH); Department of Cell Biology, State University of New York Downstate Health Science University, Brooklyn, NY, USA (PH)

- 1 Stamatatos L, Czartoski J, Wan Y-H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science* 2021; published online March 25. <https://doi.org/10.1126/science.abg9175>.
- 2 Muecksch F, Weisblum Y, Barnes CO, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. *Immunity* 2021; **54**: 1853–68.e7.
- 3 Chen Y, Tong P, Whiteman NB, et al. Differential antibody dynamics to SARS-CoV-2 infection and vaccination. *bioRxiv* 2021; published online Sept 10. <https://doi.org/10.1101/2021.09.09.459504> (preprint).
- 4 Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization of the SARS-CoV-2 omicron variant. *N Engl J Med* 2021; published online Dec 30. <https://doi.org/10.1056/NEJMc2119641>.
- 5 Carreno JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 omicron. *Nature* 2021; published online Dec 31. <https://doi.org/10.1038/s41586-022-04399-5>.